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Low back pain (LBP) is a common problem encountered by physicians. It is a considerable cause of morbidity and socioeconomic 
loss and is one of the most expensive musculoskeletal disorders. Conventional treatments include bed rest, analgesics, therapeutic 
exercises, lumbar or caudal epidural corticosteroids, and surgery. Several new biological therapies are being investigated for use in 
LBP and one of these is platelet-rich plasma (PRP). In this article, we summarize the current literature published on PRP concerning its 
composition, classification, and application in LBP. We believe our review will prove useful to clinicians and academics alike, inter-
ested in new developing therapies for LBP.
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Introduction
Low back pain (LBP) is a common problem and a signifi-
cant cause of morbidity and socioeconomic loss to society 
[1]. It is the second leading cause of disability in Ameri-
can adults and one of the main reasons why people under 
45-years limit their physical activity [2-4]. It imposes a 
considerable disease burden on society and is one of the 
most expensive musculoskeletal disorders [5].
When assessing patients with LBP, it is important to 
look for radicular symptoms such as radiating leg pain, 
sensory deficits, and neurologic lower limb deficits such 
as motor weakness, and altered reflexes. Many factors 
contribute to this pathological process. These include disc 
degeneration leading to herniation, facet arthropathy, 
ligamentum flavum hypertrophy, ossification of the pos-
terior longitudinal ligament, congenitally narrow neural 
foramen, ligament laxity, and subluxation [6]. Advancing 
age contributes to these pathological processes and it is 
logical to assume that with the increase in life expectan-
cies globally, the incidence of LBP will also increase [7].
Patients with LBP can often be managed conservatively 
with a combination of pharmacological and nonpharma-
cological therapies without the need for surgical or inva-
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sive procedures [2]. Conservative treatment includes bed 
rest, analgesic medications such as nonsteroidal anti-in-
flammatory drugs (NSAIDs) and acetaminophen, muscle 
relaxants, oral or parenteral steroids, and opioids as well 
as therapeutic exercises [1,2]. Should these fail, lumbar or 
caudal epidural glucocorticoid injections can be adminis-
tered for pain management. Surgery is indicated, in cases 
of pain refractory to conservative treatment or if neuro-
logical deficits develop.
New biological therapies are being investigated for use 
in LBP. One such treatment is the use of platelet-rich 
plasma (PRP). PRP is plasma containing concentrated 
platelets acquired from autologous blood. Advocates of 
PRP call it a bridge between conservative therapy and sur-
gery. Platelets are rich in cytokines and growth factors and 
these are believed to accelerate the body’s repair processes. 
They could, therefore, be beneficial for treating the in-
flamed nerves in lumbar radiculopathy and canal stenosis.
The purpose of this article is to provide a review of the 
currently available literature concerning the use of PRP in 
lumbar spine pathologies that lead to LBP. We hope this 
will prove useful to clinicians and academics interested in 
developing new therapies for LBP.
What is Platelet-Rich Plasma?
PRP is a sequestration of platelets in the plasma fraction 
of autologous blood, which when activated by an exoge-
nous agent releases a host of mediators and growth factors 
[8-14]. Normal platelet counts in the blood range from 
150,000/μL to 350,000/μL. PRP, however may contain 
platelet concentrations of up to 1,000,000/μL [14]. It is this 
concentration in 5 mL of autologous plasma that is con-
sidered to be the practical definition of PRP [9]. However 
different concentrations and volumes are used in practice.
PRP was first used in dental implant procedures [9]. Its 
use since then has been extended to areas such as oral and 
maxillofacial surgery, cardiovascular surgery, spine sur-
gery, plastic surgery, podiatric surgery, pulmonary care, 
and advanced wound care [10].
Composition of Platelet-Rich Plasma
Platelets are anucleate cell fragments derived from mega-
karyocytes in the bone marrow [10]. They contain organ-
elles such as mitochondria, ribosomes, lysosomes, and 
two types of granules, alpha and dense.
Each platelet has about 50 to 80 alpha granules [10]. 
Alpha granules contain more than 300 different proteins 
[15]. Dense granules, on the other hand, are relatively 
few in number and contain important chemicals such as 
calcium, serotonin, histamine, and different phosphate 
compounds such as adenosine diphosphate, adenosine 
triphosphate, and guanosine diphosphate [16].
Platelets are a storehouse of important growth factors 
such as platelet-derived growth factor (PDGF), transform-
ing growth factor-beta (TGF-β), insulin-like growth fac-
tor 1, vascular endothelial growth factorm and epithelial 
growth factor [9,10,14,17]. When released from degranu-
lated platelets they mediate healing and play important 
roles in chemotaxis and migration, angiogenesis, and 
cell proliferation and differentiation. All these processes 
ultimately lead to repair [17]. There are also several cyto-
kines, chemokines, and metabolites released by activated 
platelets that further supplement these actions [17].
Depending on the preparation technique, PRP may or 
may not contain leukocytes. Leukocytes are thought to 
release metalloproteinases and free radicals which may be 
counterproductive to the repair process and may also in-
crease postinjection pain [9,18]. However, they may exert 
antimicrobial actions [19] and some researchers believe 
that leukocytes have crucial repair mediating enzymes as 
well [18].
Preparation of Platelet-Rich Plasma
Blood is first drawn from the patient at the time of treat-
ment. An anticoagulant is used to prevent premature 
activation of the platelets [20]. The blood sample is cen-
trifuged to separate the components into different layers 
one of which is formed by the PRP. The volume of PRP di-
rectly correlates to the baseline platelet count [21]. At this 
stage, one of two methods can be used to complete the 
preparation; the PRP method or the buffy coat method.
Platelet-Rich Plasma Method
Blood is initially centrifuged at a constant acceleration 
(“soft spin”) to concentrate platelets in the supernatant. 
The platelet-containing plasma is then separated into a 
sterile tube and centrifuged at a higher speed (“hard spin”) 
for the second time to acquire the platelet concentrate. 
This step leads to the creation of the PRP (lower one-third 
the platelet concentrate) and platelet-poor plasma (PPP) 
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(the upper two-thirds of the platelet concentrate) [20].
Buffy Coat Method
The whole blood must initially be stored at a cool tem-
perature (range, 20°C to 24°C) before centrifugation [20]. 
High-speed centrifugation of the whole blood sample 
forms three layers; a superficial layer (PPP), an inter-
mediate layer also called the “buffy coat” (platelets and 
white blood cells [WBCs]) and a deep layer consisting of 
red blood cells (RBCs). The buffy coat is then separated 
and centrifuged at a lower speed, yielding a layer of PRP, 
which is separated from the resulting solution [20,21].
Classification of Platelet-Rich Plasma
A standardized classification of PRP will increase the 
standardization of PRP reporting and the resultant data 
comparability. A wide range of classification systems have 
been recommended by different authors but the four main 
classification systems are mentioned below.
Mishra et al. [22] categorize PRP preparations into four 
main types depending on the concentration of PRP, the 
WBC content, and the activation status. Type 1 and type 
2 PRP have WBC levels that are higher than the baseline. 
They differ in their activation status by an exogenous ac-
tivator, such as calcium or thrombin. Type 2 is activated 
whereas type 1 is not. Similarly, type 3 and type 4 PRP 
have minimal WBCs and type 3 is not activated by an 
exogenous activator while type 4 is. Each group is then 
further subdivided based on the platelet concentration. If 
it is over 5 times higher than the baseline it is classed as 
subgroup A, if not, it is in subgroup B. Mishra’s classifica-
tion was acceptable for PRP preparations available in 2006 
[13]. Mautner et al. [13], however, deem it insufficient as 
advancing technology, such as the development of double 
spin suspension systems, has allowed higher concentra-
tions of platelets, with little or no neutrophils and RBCs in 
the PRP.
In 2009, Dohan Ehrenfest et al. [23,24] published an-
other system, which classified PRP according to its platelet 
and leukocyte concentration and the absence or presence 
of fibrin. PRP was divided into pure PRP; leukocyte and 
PRP; pure platelet-rich fibrin (PRF); and leukocyte and 
PRF [23,24]. According to Mautner et al. [13], this ap-
proach is limited by its inability to be applied in nonop-
erative conditions due to the limited use of fibrin and the 
lack of information on RBC and WBC concentrations.
The “PAW” classification system was proposed by De-
Long et al. [25] in 2012. This classification is based on the 
concentration of platelets, the activation status, and the 
WBC and neutrophil content relative to baseline [25]. The 
concentration of platelets ranged from P1 (baseline) to P4 
(>1.2 million platelets/mL). Activation was either exog-
enous or nonexogenous and WBCs and neutrophils above 
or below baseline [25]. Mautner et al. [13], however, argue 
that this classification also failed to include RBCs and its 
categorization of WBCs and neutrophils into above and 
below baseline greatly underestimated their roles in PRP 
action.
In 2015, Mautner et al. [13] introduced their own classi-
fication system—the platelet, leukocyte, RBCs, and activa-
tion (PLRA) system. They classified PRP according to the 
following parameters [13]: (1) the concentration of plate-
lets, the total number of platelets and injected volume; (2) 
the concentration of leukocytes; (3) the concentration of 
RBC; and (4) activation by exogenous agents. The features 
of the PLRA classification are summarized in Table 1.
Intra Facet and Ligament Injections
Facet joints have been implicated in 40% of cases of spine 
pain [6]. However, we found only three studies that investi-
gated the results of PRP injections into the facet joints and 
the surrounding ligaments. Aufiero et al. [6] published a 
case series of five patients in 2015. PRP was injected bilat-
erally at multiple levels of the cervical spine of two patients. 
Two patients received PRP injections bilaterally in their 
lower lumbar levels and one patient had injections in the 
Table 1. PLRA classification system proposed by Mautner et al. [13]
PLRA classification Criteria




L: leukocyte contenta) >1% +
<1% -
R: red blood cell contentb) >1% +
<1% -
A: activation Yes +
No -
PLAR, platelet, leukocyte, red blood cells, and activation.
a)If white blood cells are present (+), the percentage of neutrophils should be 
reported. b)The method of exogenous activation should be reported.
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lower thoracic and upper lumbar levels. PRP was injected 
into the facet joints, capsule, supraspinous, and infraspi-
nous ligaments under ultrasound or fluoroscopic guidance. 
All five cases reported a significant improvement in their 
pain. However, given the absence of a control group, it is 
not possible to conclude whether this treatment is better or 
worse than the established modalities.
Another study enrolled 19 patients with lumbar facet 
joint syndrome and injected autologous PRP into the 
lumbar facet joints under X-ray fluoroscopic guidance 
[26]. Pain control outcomes were measured using the Vi-
sual Analog Scale (VAS), Roland–Morris Disability Ques-
tionnaire (RMQ), Oswestry Disability Index (ODI), and 
modified MacNab criteria. Significant pain reduction was 
experienced by nine patients (47.37%) immediately after 
treatment, 14 (73.68%) at 1 week, and 15 patients (78.95%) 
at 1 month, 2 months, and 3 months [26].
In 2017, a prospective comparative study randomized 
46 patients into group A (intra-articular PRP) and group 
B (intra-articular local anesthetic and corticosteroid) [27]. 
Pain outcomes were measured using VAS, RMQ, ODI, 
and modified MacNab criteria. Both groups achieved 
statistically significant pain relief. Subjective satisfaction 
based on the modified MacNab criteria and the objec-
tive success rate for group B peaked (80% and 85%) after 
1 month, but it was only 50% and 20% after 6 months. 
However, for group A, they increased over time. It was 
hence concluded that autologous PRP is a superior treat-
ment option for longer duration efficacy [27]. This study 
addressed the previous two studies’ lack of control group; 
however, it was limited by the small number of patients. 
More studies, with larger sample sizes and double-blind-
ing, are needed for conclusive evidence.
Epidural Injections
Epidural steroid injections (ESIs) are an established 
method of pain management in lumbar radiculopathy. In 
fact, ESIs are the most widely performed pain manage-
ment procedure in the world [28]. Their use has been 
documented and corroborated by more than 45 placebo-
controlled trials and dozens of systematic reviews [28]. 
They may be injected trans foramen, intralaminar, or cau-
dally via the sciatic hiatus. The trans foramen approach 
has shown to be the most efficacious as it is more target-
specific, has greater ventral epidural spread and is associ-
ated with lower chances of dural puncture [28].
Steroids work by inhibiting the arachidonic acid cas-
cade thereby limiting inflammation of the lumbar nerve 
roots. Risk factors for this procedure include hemorrhage 
or hematoma formation, infection, paralysis, or spinal 
headache [4,10]. Steroid injections have also been im-
plicated in spinal cord embolisms and septic and aseptic 
meningitis [4,10].
The injection of PRP into the epidural space for lum-
bar radiculopathy is uncharted territory. In our literature 
search, we were able to find only two papers describing 
the injection of PRP in place of steroids.
The first study was a pilot study published in 2016 by 
Bhatia and Chopra [4]. Using the intralaminar approach, 
they injected 5 mL of PRP into the epidural spaces of 10 
patients. Patients were followed up using the modified 
Oswestry Disability Questionnaire (MODQ), Straight Leg 
Raising Test (SLRT), and VAS scores. All patients showed 
sustained improvement up to the 3-month follow-up peri-
od. VAS scores for all patients were 4 or less except for one 
patient who scored 5. Most of the patients also showed an 
improvement in MODQ and SLRT to less than 30% and 
greater than 70, respectively.
The second paper was a case study published by Lemper 
et al. [10]. They report a 35-year-old female being chroni-
cally managed for neck pain and LBP with radiation into 
her arms and legs. She had a history of a motor vehicle 
collision, after which these symptoms arose. She had re-
ceived multiple cervical and lumbar ESIs which gave her 
only a few weeks of relief before her pain returned. She 
had also undergone 6 months of physical therapy with no 
reported improvement in her symptoms.
She then became pregnant and the injections were 
abandoned as steroids can lead to pregnancy complica-
tions, prolonged labor, and in severe cases fetal and mater-
nal death [10]. She agreed to epidural PRP injections and 
reported improvements in both her neck and lower back 
pain. There were no adverse effects of the treatment on 
the pregnancy and the patient delivered a healthy child.
Though both articles report positive results of epidural 
PRP injections, there is a need for further studies before 
wider use. Comparative studies with conventional thera-
pies such as NSAIDs, physical therapy, and epidural ste-
roids would help determine the efficacy of PRP compared 
to that of already established modalities.
A significant limitation of epidural PRP is that patients 
may not achieve acute pain relief. For this Bhatia and 
Chopra [4] suggest the supplementation of PRP with 
Platelet Rich Plasma and Low Back PainAsian Spine Journal 121
painkillers. Again, more studies are required to evaluate 
this.
Intradiscal Injections
An intervertebral disc (IVD) is a pad of cartilage between 
two adjacent vertebrae that acts as a shock absorber. It 
plays a vital role in stabilization as well as flexion and ex-
tension of the spine [29].
Being the largest avascular structure in an adult human, 
the IVD depends upon passive diffusion from the end-
plate vessels for nutrition. It is supplied by branches of the 
metaphyseal arteries around the outer annulus [30]. Since 
the IVD lacks a proper nutritional supply of growth fac-
tors, it has minimum self-repairing ability [29,31].
Degenerative disc disease (DDD) involves the degenera-
tion of one or more IVDs [32] and depends upon genetic 
and environmental factors [31]. The patient presents with 
pain that may radiate [32]. Current treatment options in-
clude conservative approaches such as anti-inflammatory 
drugs and physiotherapy, as well as spinal surgery [29]. 
Not only do current treatments completely ignore the un-
derlying cause but treatment options like surgery restrict 
patient mobility and can interrupt their daily activity for 
nearly 6 weeks [32]. An alternative therapy like stem cells 
or growth factors might be a possible cheap solution to 
treat this pathology. It can be performed in outpatient 
facilities and takes very little time [5]. The purpose of 
intradiscal injections is to supply a high concentration of 
growth factors to poorly nourished IVD for growth and 
repair.
Several studies investigating the use of PRP on IVDs 
have been published [29-33] (Table 2). Obata et al. [31] 
induced disc degeneration in 12 rabbits by an annular 
puncture in two noncontiguous discs. This produced 
disc narrowing within 4 weeks. Autologous PRP or PPP 
were isolated from fresh blood. Releasate isolated from 
clotted PPP or PRP or phosphate-buffered saline (PBS) 
control was injected at the site of the degenerating disc. 
It was found that PRP releasate produced a statistically 
significant restoration of disc height. The PRP treatment 
group also had a higher number of chondrocyte-like cells. 
However, magnetic resonance imaging (MRI), T2 quan-
tification did not show a statistical difference in mean T2 
values of nucleus pulposus and annulus fibrosus among 
the three groups.
Another article demonstrates a similar finding. PRP was 
used with bone marrow-derived mesenchymal cells (BM-
SCs). A total of 30 rabbits were used in this experiment: 
10 were in the PRP–BMSC group, 10 were injected with 
PRP or PBS, while another 10 were given no intervention 
and served as controls. MRI revealed the reparative effect 
of PRP in the PRP–BMSC group and PRP group. On the 
other hand, disc degeneration was unaffected in the PBS 
group. MRI results at 8 weeks demonstrated a statistically 
significant improvement in disc restoration in the PRP–
BMSC group as compared with other groups. The study, 
therefore, indicates better efficacy of PRP if used together 
with BMSCs [29].
Moving on to clinical studies, Comella et al. [32] report 
a study on 15 patients undergoing liposuction to extract 
mesenchymal cells. PRP was used with the adipose tissue 
for IVD injections. The results indicated a statistically sig-
nificant improvement in flexion (pelvis, lumbar, and total 
flexion), pain, VAS, present pain intensity, and the scores 
of other questionnaires. There were no serious complica-
tions. ODI and Beck Depression Inventory scores showed 
improvement but with no statistical significance. The Dal-
las Pain Questionnaire showed an improvement in daily 
and work and leisure activities. However, there was an 
increase in anxiety and depression scores and a drop in 
social interest. The study, however, lacked a control group 
and further investigation is required. Levi et al. [33] state 
a similar finding in another prospective trial involving 22 
patients with discogenic LBP who were treated with PRP 
IVD injections. The therapy was considered successful 
if the patients managed a 30% improvement in ODI and 
50% improvement in VAS after the 1 month, 2 months, 
and 6 months following the injection. At 6 months, 47% 
had a successful outcome in ODI and 41% had a success-
ful outcome in VAS according to the criteria set. The trial 
showed encouraging preliminary data supporting the use 
of intradiscal PRP injections. This study also lacked a con-
trol group.
Another study conducted by Tuakli-Wosornu et al. [30] 
consisted of adult patients with chronic (≥6 months), 
moderate-to-severe lumbar discogenic pain that was 
unresponsive to conservative treatment. The 58 study 
participants were randomized to receive intradiscal PRP 
or contrast agent after provocative discography. In the 
PRP group, 56% were satisfied with the treatment com-
pared with 17% of the control group. Those who received 
PRP maintained their Functional Rating Index for 1 year. 
There were no side effects or complications such as disc 
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space infection, neurologic injury, or progressive hernia-
tion after receiving the PRP injection.
To summarize, intradiscal PRP injections can be a safe, 
cheap, and feasible treatment to counter IVD degenera-
tion associated LBP. It is vital to administer PRP early in 
the course of the treatment to stimulate the growth of the 
remaining cells in the disc. If the treatment is delayed, the 
number of active cells in the disc will be at a minimum 
and the PRP will possibly fail to induce the desired impact 
[29]. Although intradiscal PRP injections show promising 
results, there is a need for more studies with larger sample 
sizes and adequate control groups. Further studies are also 
needed to define the subset of patients most likely to ben-
efit from this treatment.
Spinal Fusion
Spinal fusion is a procedure used to treat chronic lumbar 
pain due to DDD [34]. The procedure involves joining the 
vertebrae, to eliminate movement between them, result-
ing in a continuous bone. The posterolateral fusion of two 
adjacent vertebrae is a frequently performed procedure on 
the lumbar spine [34,35]. Bone autograft extracted from 
the iliac spine is considered to be the gold standard [34-
36]. The rationale behind this procedure is that the graft 
has osteoinductive and osteoconductive properties and 
contains osteogenic cells that will result in new bone for-
mation [36].
Harvesting the bone graft can result in serious compli-
cations such as donor morbidity, bleeding from the har-
vest site, nerve injury, and subsequent chronic pain and 
infection [34,36-38]. Moreover, the process requires a lot 
of time and may still result in inadequate availability of 
the graft [34,37].
The use of PRP in spinal fusion surgery could be a pos-
sible solution to this problem. TGF-β and PDGF found in 
the alpha granules of the concentrated platelets encourage 
osteoblast proliferation [34,39-42]. They are a cheap and 
natural pool of growth factors that is available instantly in 
the operating theater [34,37,40]. They also promise faster 
recovery times [40]. Current data available in the litera-
ture demonstrate encouraging results.
Landi et al. [40] described 14 patients who underwent 
posterolateral fusion. In each patient, PRP along with au-
tologous bone was used on one-half of the operative field 
and autologous bone graft alone on the other half. All 
patients underwent serial CT scans and plain X-rays at 3 
and 6 months after surgery to evaluate bone fusion. At 3 
months, the authors found an increased rate of fusion in 
the PRP operated field as compared to the one in which 
only the autologous graft was used. Although this differ-
ence was balanced out at 6 months, bone density in the 
PRP operated field remained higher [40].
A similar finding was reported by Tarantino et al. [34] 
in 20 patients who underwent posterolateral arthrodesis 
in lumbar spine surgery. In one hemifield, cancellous 
bone with PRP was used while in the other cancellous 
bone with saline was applied. The results after 6 months 
demonstrated a statistically significant increase in bone 
density and fusion rates in the PRP hemifield compared to 
the half in which cancellous bone alone was used.
Lowery et al. [43] reported a retrospective study of 19 
patients with 100% fusion rates who underwent spinal 
fusion with the use of autologous growth factors (AGF) 
acquired from ultrafiltration of platelets, along with the 
bone graft and hydroxyapatite. Similarly, intertransverse 
lumbar fusion autograft alone was shown to produce less 
bone maturation in comparison with the addition of PRP 
to the autograft [44].
Some articles, however, report that PRP has no use in 
spinal fusion and some even describe negative outcomes. 
Sys et al. [41] investigated the effects of PRP in monoseg-
mental posterior lumbar interbody fusion in 40 patients. 
The VAS score and ODI differences between the “allograft 
with PRP” group and “allograft only” group were statis-
tically insignificant. Another article demonstrated the 
inhibitory effects of AGF used in conjunction with iliac 
crest grafts in posterolateral spinal fusion surgery [45].
Intramuscular Injections
The lumbar multifidus (LMF) muscle stabilizes the spine 
because of its morphology and its anatomical position. 
Its fibers are short with a high cross-sectional area which 
supports the muscle’s role in spine stabilization rather 
than motion. The relation between lower back pain and 
the multifidus muscle has been well established by several 
studies [46]. In chronic LBP with monosegmental disc de-
generation, the size and cross-sectional area of the muscle 
decreases [46].
We found one study that reports the role of platelet leu-
kocyte rich plasma (PLRP) injections on LMF muscle [46]. 
PLRP intramuscular injections were given to 115 patients 
and the outcomes were monitored using the Numeric Rat-
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ing Scale and ODI. Both scores showed a statistically sig-
nificant improvement. The overall successful outcome was 
71.2%, thus demonstrating that PLRP injections in the 
LMF muscle can possibly prove to be a safer and cheaper 
approach to treat LBP. The lack of a control group, how-
ever, limits further decisive conclusions.
Limitations of Platelet-Rich Plasma
The premature release of growth factors through degranu-
lation, the fact that growth factors are released for a short-
er duration of time after activation, and their susceptibility 
to proteolytic enzymes may render PRP ineffective [35,37]. 
Variable concentrations and quality of PRP because of 
the differences between individuals also limit its use and 
contributes to some of the negative results published. 
Lastly, the optimal time for PRP implantation, the optimal 
concentration of platelets in the PRP sample and whether 
PRP should be used in the inactivated or activated form is 
yet to be established [35,39].
Conclusions
In conclusion, the use of PRP in various injections, such 
as intrafacet, intraligament, epidural, intradiscal, spinal 
fusion, and intramuscular injections, has yielded promis-
ing results that have been reported in recent literature. 
However, further studies are required with larger sample 
sizes and control groups to prove its efficacy and establish 
its routine use in surgery. The stage of LBP at which PRP 
provides the most advantage and how PRP injections 
perform in comparison to conservative measures such as 
NSAIDS and physiotherapy are also areas for further in-
vestigation.
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